Sanofi India

The page offers a demonstration video for using the Sanofi Lantus cartridge with the AllStar device in multiple languages.

The IDF Diabetes Atlas estimates 74 million Indians aged 20–79 live with diabetes, risking severe complications if untreated.

The page explains how the gut influences overall health, including digestion and immunity, and outlines ways to support digestive wellness.

Constipation is a persistent digestive issue affecting well-being, but understanding its causes, symptoms, and treatments can help manage it.

Constipation causes discomfort and disrupts daily activities, varying in impact among individuals.

Media room, company statements

Sanofi Healthcare India Pvt. Limited announces receipt of marketing authorization for Rezurock (Belumosudil Tablets) in India.

Ajaypal was appointed Head of Vaccines at Sanofi Healthcare India Private Limited (SHIPL) in August 2026.

Southeast Asia & India Established Products Medical Lead

Conoce más sobre quiénes somos y nuestro aporte para mejorar la salud humana.

The company develops medicines and vaccines to address patient needs, with 40 million potential beneficiaries in its current pipeline.

A girl in a classroom taking part in the Kids and Diabetes in Schools program

Contact for Consumer Healthcare & Over-The-Counter (OTC) Products:

Sanofi House, CTS No.117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072

Sanofi is a biopharmaceutical company using research, development, and AI to create innovative medicines and vaccines.

Sanofi India reports a **53.6% year-over-year profit increase** to **₹117 crore** in Q3 2026, up from ₹76 crore in the same period last year. The company declares an **interim dividend of ₹75 per share** for shareholders. The growth reflects stronger financial performance in its third-quarter results.

Oct 2026CNBC TV18News article

Sanofi India reports a **54% increase in net profit** to **Rs 117 crore** in Q3 FY 2026, up from Rs 76 crore in the same period last year. The company also declares an **interim dividend of Rs 75 per share** for shareholders. The results reflect stronger financial performance in the quarter.

Oct 2026NDTV ProfitNews article

Dr. Reddy’s Laboratories partners with Sanofi Healthcare India to introduce **Beyfortus (nirsevimab)**, a monoclonal antibody injection for preventing **RSV lower respiratory tract disease (LRTD)** in newborns and infants. The drug, already available in markets like the U.S. and EU, marks Dr. Reddy’s entry into India’s immunization sector. Beyfortus targets a respiratory virus that poses significant risk to vulnerable pediatric populations.

Apr 2025eHealth MagazineNews article

Rodolfo Hrosz is leaving his role as Managing Director of Sanofi India Limited. His departure will take effect on April 30, 2025, marking the end of his tenure at the company’s Indian subsidiary. Sanofi India operates in the pharmaceutical sector, focusing on healthcare solutions across the country.

Apr 2025Board StewardshipNews article